

March 4, 2014



DelMar Pharmaceuticals to Present at the 26th Annual ROTH Capital Conference

VANCOUVER, British Columbia and MENLO PARK, Calif., March 4, 2014 /PRNewswire/ - [DelMar Pharmaceuticals, Inc.](#) (OTCQB: DMPI) ("DelMar" and "DelMar Pharma") a pharmaceutical company developing its VAL-083 chemotherapy as a potential new therapy for glioblastoma multiforme, today announced that Jeffrey A. Bacha, President and CEO of DelMar Pharmaceuticals, Inc., will present at the upcoming 26th Annual ROTH Capital Conference.

Mr. Bacha will make a corporate presentation to prospective corporate partners and investors at 9:00 AM PT (12:00 Noon ET) on Tuesday, March 11th at the Ritz Carlton, Dana Point, California.

Mr. Bacha will provide an update on the company's ongoing Phase I/II refractory glioblastoma clinical trial with VAL-083 and strategies for building the company's business including the Company's intention to apply for an initial listing on the NYSE or NASDAQ at the earliest available opportunity.

DelMar Pharma representatives will be available for 1-on-1 meetings throughout the event.

At the time of the presentation, a live webcast of Mr. Bacha's presentation will be available at <http://wsw.com/webcast/roth28/DMPI>. DelMar recommends registering at least 15 minutes prior to the scheduled start time to ensure timely access. A replay will be available following the presentation and accessible on www.delmarpharma.com for 90 days following the event.

About DelMar Pharmaceuticals

Del Mar Pharmaceuticals was founded in 2010 to develop and commercialize proven cancer therapies in new orphan drug indications where patients are failing modern targeted or biologic treatments. The Company's lead asset, VAL-083, is currently undergoing clinical trials in the United States as a potential treatment for refractory glioblastoma multiforme (GBM), the most common and aggressive form of brain cancer. VAL-083 benefits from extensive clinical research sponsored by the U.S. National Cancer Institute (NCI), and is currently approved for the treatment of chronic myelogenous leukemia (CML) and lung cancer in China. Published pre-clinical and clinical data suggest that VAL-083 may be active against a range of tumor types via a novel mechanism of action.

Safe Harbor Statement

Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities

Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations, but are subject to a number of risks and uncertainties. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the Company's ability to develop, market and sell products based on its technology; the expected benefits and efficacy of the Company's products and technology; the availability of substantial additional funding for the Company to continue its operations and to conduct research and development, clinical studies and future product commercialization; and, the Company's business, research, product development, regulatory approval, marketing and distribution plans and strategies. These and other factors are identified and described in more detail in our filings with the SEC, including, our current reports on Form 8-K. We do not undertake to update these forward-looking statements made by us.

For further information, please visit www.delmarpharma.com; or contact **Jeffrey A. Bacha, President & CEO (604) 629-5989** or **Booke & Company Investor Relations, admin@bookeandco.com**

SOURCE DelMar Pharmaceuticals, Inc.